Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | VP, Finance & CFO | April 29, 2016 | December 23, 2016 |
| Lite Strategy, Inc.MEIP · Entity 7396 | Chief Financial Officer | July 05, 2022 | July 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HERON THERAPEUTICS, INC. /DE/
Report date April 29, 2016 · Filed December 23, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,798 |
Ending reported balance
After 2016-10-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-04-29 · Other · Acquired 577 · Balance 3,260 F1: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan. Row 2 · 2016-10-31 · Other · Acquired 538 · Balance 3,798 F1: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan.
Lite Strategy, Inc.
Report date July 05, 2022 · Filed July 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2032-07-05 | Direct | 350,000 |
Reported balance
After 2022-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-05 · Grant · Acquired 350,000 · Balance 350,000 F1: One-quarter of such options shall vest on July 5, 2023 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 5, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2031-07-01 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 200,000 F2: One-quarter of such options vested on July 1, 2022 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2027-04-03 | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 150,000 F3: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2027-07-06 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 50,000 F3: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2028-06-22 | Direct | 130,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 130,000 F3: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.28 · Expires 2028-07-12 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 100,000 F4: One-quarter of such options vested on July 12, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 12, 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2029-07-01 | Direct | 230,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 230,000 F5: One-quarter of such options vested on July 1, 2020 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.49 · Expires 2030-07-02 | Direct | 230,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 230,000 F6: One-quarter of such options vested on July 2, 2021 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: One-quarter of such options shall vest on July 5, 2023 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 5, 2023.
F2: One-quarter of such options vested on July 1, 2022 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2022.
F3: All of such options are presently exercisable.
F4: One-quarter of such options vested on July 12, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 12, 2019.
F5: One-quarter of such options vested on July 1, 2020 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2020.
F6: One-quarter of such options vested on July 2, 2021 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 2, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2022 Filed Jul 7, 2022 20:23 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0000899243-22-025702 · doc4.xml · derivative · entry 1 Drazba Brian G. · CIK 0001507369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-07-05 F1 · derivative.exercise_date: One-quarter of such options shall vest on July 5, 2023 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 5, 2023. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 22:51 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001209191-21-045643 · doc4.xml · derivative · entry 1 Drazba Brian G. · CIK 0001507369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: One-quarter of such options shall vest on July 1, 2022 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2022. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 17:09 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 230,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0000899243-20-018611 · doc4.xml · derivative · entry 1 Drazba Brian G. · CIK 0001507369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2030-07-02 F1 · derivative.exercise_date: One-quarter of such options shall vest on July 2, 2021 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 2, 2021. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 17:55 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | PurchaseCommon Stock | 12,500 | $1.60 | $20,000.00 |
DisclosureSEC source: 0001209191-19-061471 · doc4.xml · nonDerivative · entry 1 Drazba Brian G. · CIK 0001507369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 19:35 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 230,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-19-040984 · doc4.xml · derivative · entry 1 Drazba Brian G. · CIK 0001507369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2029-07-01 F1 · derivative.exercise_date: One-quarter of such Options shall vest on July 1, 2020 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2020. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 21:32 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001209191-18-042681 · doc4.xml · derivative · entry 1 Drazba Brian G. · CIK 0001507369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-07-12 F1 · derivative.exercise_date: One-quarter of such Options shall vest on July 12, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 12, 2019. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 18:33 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0000899243-18-018110 · doc4.xml · derivative · entry 1 Drazba Brian G. · CIK 0001507369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2028-06-22 F1 · derivative.exercise_date: One-quarter of such Options shall vest on June 22, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on June 22, 2019. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 18:22 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantOption to purchase shares of common stock · Derivative | 50,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001209191-17-044517 · doc4.xml · derivative · entry 1 Drazba Brian G. · CIK 0001507369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock par value $0.00000002 · 50,000 shares Expires 2027-07-06 F1 · derivative.exercise_date: One-quarter of the options will vest on July 6, 2018; the remaining three-quarters of the options will vest in equal monthly installments over the following thirty-six months. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 21:55 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantOption to purchase shares of common stock · Derivative | 150,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-17-025201 · doc4.xml · derivative · entry 1 Drazba Brian G. · CIK 0001507369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock par value $0.00000002 · 150,000 shares Expires 2027-04-03 F1 · derivative.exercise_date: One-quarter of the options will vest on April 3, 2018; the remaining three-quarters of the options will vest in equal monthly installments over the following thirty-six months. Read SEC document |
| October 31, 2016 Filed Dec 23, 2016 21:03 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 538 | $12.62 | $6,790.91 |
DisclosureSEC source: 0001209191-16-156658 · doc4.xml · nonDerivative · entry 2 Drazba Brian G. · CIK 0001507369 · VP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,798 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan. Read SEC document |
| April 29, 2016 Filed Dec 23, 2016 21:03 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 577 | $18.22 | $10,515.25 |
DisclosureSEC source: 0001209191-16-156658 · doc4.xml · nonDerivative · entry 1 Drazba Brian G. · CIK 0001507369 · VP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,260 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.